Pasar al contenido principal

BIOIMPRESION 3D DE SCAFFOLDS MAGNETO-PIEZOELECTRICOS MIMETICOS DE TENDON

PID2023-152062OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Surface-engineered gold nanorods for targeted delivery of PD-L1 siRNA and cancer chemo-phototherapy

  • Arellano, Lilia
  • Villar Álvarez, Eva
  • Cambón Freire, Adriana
  • Costa Santos, Alba
  • Pardo Montero, Alberto
  • Topete Camacho, Antonio
  • Barbosa Fernández, Silvia
  • Taboada Antelo, Pablo
Nowadays, cancer remains a global leading cause of death, with therapeutic advances often hindered by drug resistance and adverse side effects. The integration of nanotechnology with immunotherapy has emerged as a promising approach to enhance specificity and efficacy of oncological treatments. A key immunotherapeutic target is the so-called programmed death-ligand 1 (PD-L1), a protein that enables tumors to evade immune surveillance and increase their chemotherapy resistance. Interestingly, RNA interference using small interfering RNA (siRNA) targeting PD-L1, has shown potential in reactivating anti-cancer immune responses. However, efficient delivery of siRNA still faces challenges in terms of stability, cellular uptake, and/or targeted release. In this study, we developed a multifunctional theranostic nanoplatform based on gold nanorods (GNRs) surface-engineered through a layer-by-layer assembly with poly(styrene sulfonate), poly(L-lysine), and hyaluronic acid, to provide enhanced stability and active targeting towards CD44 receptors overexpressed in cancer cells. Within the polymeric multilayers PD-L1 siRNA, doxorubicin and indocyanine green were loaded for multimodal therapeutic activity. The anti-tumor effect, siRNA transfection efficiency and cell death mechanism of the nanoplatform was evaluated on HeLa cells expressing PD-L1 and CD44 and Balb/3T3 fibroblasts. The surface-engineered GNRs-based nanosystem efficiently transfected PD-L1 siRNA and allowed subsequent application of multimodal chemo-, photodynamic and photothermal therapy with enhanced cytotoxicity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Liposomes as “Trojan Horses” in Cancer Treatment: Design, Development, and Clinical Applications

  • Sabín, Juan
  • Santisteban-Veiga, Andrea
  • Costa-Santos, Alba
  • Abelenda, Óscar
  • Domínguez-Arca, Vicente
31 pages, 2 tables, 6 figures, Liposomes started to be studied for drug delivery in 1970s, taking advantage of their ability to encapsulate hydrophilic and hydrophobic drugs using biodegradable and biocompatible molecules. Nowadays, they remain one of the most promising strategies for drug delivery not only in cancer treatment but also in gene therapies and vaccines. The design and development of liposomal systems have evolved significantly over the past decades, moving from conventional formulations to advanced, stimulus-responsive, and multifunctional nanocarriers. Analogous to the myth of the Trojan Horse, liposomes must mislead the host immune system to reach the interior of cancer cells in order to deliver the therapeutic payload. There are many barriers that liposomes have to overcome to circulate through the bloodstream and specifically target cancer cells without damaging other tissues. Crucial parameters such as lipid composition, particle size, zeta potential, and PEGylation have been systematically optimized to enhance pharmacokinetics and biodistribution and to improve delivery efficiency. Furthermore, conjugation with antibodies, peptides, or small molecules has enabled active targeting, while stimuli such as pH, temperature, and enzymatic activity have been exploited for controlled drug release within the tumor microenvironment. Such innovations have laid the groundwork for translating liposomal formulations from the bench to clinical applications. In this paper, we evaluate the physicochemical features of liposomal design that underpin their suitability and efficacy for anticancer drug delivery. We aimed to focus on two main aspects: conducting an exhaustive review of the physicochemical parameters of liposomal drugs that have already been approved by regulatory agencies, while maintaining a pedagogical approach when explaining the key design parameters for the optimal design of liposomes in oncology in detail, This research was supported by funding from the Consellería de Educación, Ciencia, Universidades y Formación Profesional of the Xunta de Galicia through the industrial PhD program (code IN606D). A. C.-S. thanks Agencia Estatal de Investigación for her FPI PRE2020-09572. V. D.-A. thanks Xunta de Galicia for his grant IN606B-2023/006. The authors also thank Agencia Estatal de investigación for projects PID2019-109517RB-I00, PID2022-142682OB-I00 and PID2023-152062OA-I00, Xunta de Galicia for project GFCP ED41C 2022/18, and the European Union for project PCI2022-134981-2, Peer reviewed